Zeposia (ozanimod)

money trend loss dollar stock down

Biotech

Ventyx misses with investors amid comparisons to BMS, Pfizer

The phase 2 hit its primary endpoint, but doubts about whether the candidate has an edge over rival S1P1 modulators sent Ventyx’s stock down.

Nick Paul Taylor Oct 10, 2023 6:30am

missed the mark

Chasing BMS and Pfizer, Connect fails ulcerative colitis trial

May 4, 2022 7:53am

Bristol Myers says Celgene buyout could boost sales to $20B

Jun 25, 2020 11:45am